Defining imaging biomarker cut points for brain aging and Alzheimer's disease

By Clifford R. Jack Jr., H. Wiste, S. Weigand, Terry M. Therneau, V. Lowe, David S. Knopman, Jeffrey L. Gunter, Matthew L. Senjem, David T. Jones, Kejal Kantarci and 6 more. Alzheimer's & Dementia, 2017

842 citations recorded by the source corpus.

Our goal was to develop cut points for amyloid positron emission tomography (PET), tau PET, flouro‐deoxyglucose (FDG) PET, and MRI cortical thickness.

Subfields: Genetics, Psychiatry and Mental health, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/8eb8de2b4ae245a20f5454ab933fa30d0d3d6dd5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Psychiatry and Mental health

1. Reisa A. Sperling
2. William J. Jagust
3. Clifford R. Jack Jr.
4. Thomas J. Montine
5. Suzanne L. Baker
6. Gil D. Rabinovici
7. José Luis Molinuevo
8. Samuel N. Lockhart

In Radiology, Nuclear Medicine and Imaging

1. Reisa A. Sperling
2. Clifford R. Jack Jr.

Citations in the corpus

• Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease (2017, methodology): “This further supports the argument that regions affected early by tau pathology such as entorhinal cortex should be incorporated into regional tau PET biomarkers (as done by Jack et al., 2016b).”
• NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, positive): “A three-range approach might also be useful where the three ranges are defined by two cut points, one lenient and the other more conservative [16,110,111].”